← Back to graph

Prescription

elivaldogene autotemcel Skysona

Selected indexed studies

Elivaldogene Autotemcel: First Approval. (Mol Diagn Ther, 2021) [PMID:34424497]
Risk and Benefit Assessment of Gene Therapy with Lentiviral Vectors and Hematopoietic Stem Cells: The Skysona Case. (Hum Gene Ther, 2025) [PMID:40887817]

_Worker-drafted node — pending editorial review._

Connections

elivaldogene autotemcel Skysona is a side effect of

Renal ImpairmentNegative Condition

Sources

Elivaldogene Autotemcel: First Approval. (2021) pubmed
Risk and Benefit Assessment of Gene Therapy with Lentiviral Vectors and Hematopoietic Stem Cells: The Skysona Case. (2025) pubmed

Local graph